
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Gastric Cancer Screening & Surveillance: A Comparative Review
US (AGA) vs. European (MAPS III) Guidelines</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Gastric Cancer Screening & Surveillance: A Comparative Review</strong><br><em>US (AGA) vs. European (MAPS III) Guidelines</em></summary>
            <div>
                <ul><li>- <b>Source 1 (US)</b>: AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review (Gastroenterology 2025).</li><li>- <b>Source 2 (Europe)</b>: Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025 (Endoscopy 2025).</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the recommended surveillance interval for high-risk gastric precancerous conditions (e.g., OLGIM III/IV) according to the MAPS III guideline?</li><li>- The AGA guideline notes that in some US populations, GC incidence approaches that of colorectal cancer. Which group is this?</li><li>- According to MAPS III, what is the lymph node metastasis (LNM) risk threshold for a resection to be considered 'curative/low-risk'?</li><li>- The AGA guideline states that H. pylori eradication reduces GC incidence by what percentage in non-US RCTs?</li><li>- For a differentiated gastric lesion with ulceration, what is the maximum size for which ESD is recommended as standard treatment according to MAPS III?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Rationale & Epidemiology</strong></summary>
            <div>
                <ul><li>- Gastric Cancer (GC) is a leading cause of preventable cancer death worldwide.</li><li>- Early detection is critical, as 5-year survival is poor when diagnosed at a late stage (<q>32%</q> in the US) but excellent for early-stage disease (<q>95-99%</q>).</li><li>- Both guidelines emphasize the slow, stepwise progression (<b>Correa cascade</b>) from inflammation ---> atrophy ---> intestinal metaplasia ---> dysplasia ---> carcinoma, which provides a window for intervention.</li></ul>
                
        <details>
            <summary><strong>US Perspective (AGA)</strong></summary>
            <div>
                <ul><li>- Estimated <q>26,500</q> new cases and <q>11,130</q> deaths in the US in 2023.</li><li>- GC in the US is a disease of <u>disparity</u>, disproportionately affecting racial/ethnic minorities, immigrants, and underserved populations.</li><li>- Incidence in Korean Americans (<q>25.9</q> per 100,000) approaches combined colon and rectal cancer incidence in non-Hispanic White Americans (<q>29.8</q> per 100,000).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>European Perspective (MAPS III)</strong></summary>
            <div>
                <ul><li>- In 2017, over <q>1 million</q> incident cases and nearly <q>865,000</q> deaths occurred worldwide.</li><li>- Focuses on varying risk across different European regions, necessitating a geographically-stratified screening approach.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Screening Recommendations: Who & When</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: Both guidelines advocate for a <u>risk-stratified approach</u> rather than universal screening for the general population.</li></ul>
                
        <details>
            <summary><strong>MAPS III (European) Approach: <u>Population-Level Risk</u></strong></summary>
            <div>
                <ul><li>- Recommends screening based on regional <b>age-standardized rate (ASR)</b> of GC.</li></ul>
                
        <details>
            <summary><strong>Screening Criteria by ASR</strong></summary>
            <div>
                <ul><li>- <b>High-risk regions</b> (ASR > <q>20</q> per 100,000): Endoscopic screening every <q><u>2 to 3 years</u></q>.</li><li>- <b>Intermediate-risk regions</b> (ASR <q>10–20</q> per 100,000): Endoscopic screening every <q><u>5 years</u></q>, if cost-effectiveness is proven.</li><li>- <b>Low-risk regions</b> (ASR < <q>10</q> per 100,000): <u>No population-based screening</u> is recommended.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>AGA (US) Approach: <u>Individual-Level Risk</u></strong></summary>
            <div>
                <ul><li>- Focuses on <b>personalized risk assessment</b> due to the highly heterogeneous US population.</li><li>- Does not use ASR cutoffs for population-level recommendations.</li></ul>
                
        <details>
            <summary><strong>Identifiable High-Risk Groups (Best Practice Advice 1)</strong></summary>
            <div>
                <ul><li>- <u>First-generation immigrants</u> from high-incidence regions (GC incidence ≥ <q>10–12</q> per 100,000), including Eastern Europe, Andean Latin America, and East Asia.</li><li>- Individuals with a <u>family history of GC</u> in a first-degree relative.</li><li>- Non-White racial and ethnic groups (e.g., Asian, Hispanic, Black Americans) as surrogates for underlying risks.</li><li>- Individuals with certain <u>hereditary cancer syndromes</u> (e.g., Lynch, FAP, Peutz-Jeghers).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Recommended Screening Age</strong></summary>
            <div>
                <ul><li>- Suggests initiating screening at age <q><b>45</b></q>, to potentially align with average-risk colorectal cancer screening.</li><li>- For those with a family history of GC: begin screening <q><u>10 years earlier</u></q> than the youngest age of diagnosis in the family.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Consensus on Family History</strong></summary>
            <div>
                <ul><li>- Both guidelines identify a <b>first-degree relative with GC</b> as a significant risk factor warranting screening.</li></ul>
                
        <details>
            <summary><strong>MAPS III Specifics</strong></summary>
            <div>
                <ul><li>- Suggests <u>non-invasive H. pylori screening</u> and eradication for first-degree relatives between ages <q>20 and 30</q>.</li><li>- Recommends endoscopic screening at age <q>45</q> or <q>10 years before</q> the index case's diagnosis.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Primary Screening Modality: High-Quality Endoscopy</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: <u>High-quality upper endoscopy (EGD)</u> is the best and only currently acceptable test for GC screening and surveillance.</li></ul>
                
        <details>
            <summary><strong>Essential Components of a High-Quality Exam</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: Both guidelines emphasize the following for optimal detection:</li></ul>
                
        <details>
            <summary><strong>Technology & Visualization</strong></summary>
            <div>
                <ul><li>- Use of <b>high-definition white-light (HD-WLI)</b> endoscopy systems.</li><li>- Routine use of <b>virtual chromoendoscopy (VCE)</b> / image-enhanced endoscopy (IEE) like NBI or LCI.</li><li>- Thorough gastric mucosal cleansing and adequate insufflation.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Procedure & Documentation</strong></summary>
            <div>
                <ul><li>- Adequate visual inspection time.</li><li>- Systematic photodocumentation.</li><li>- Use of a systematic biopsy protocol for mucosal staging when indicated.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Biopsy Protocol for Staging Precancerous Conditions</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: A systematic biopsy protocol (e.g., <u>Updated Sydney System</u>) is crucial for histologic staging of atrophy and intestinal metaplasia.</li></ul>
                
        <details>
            <summary><strong>Core Protocol</strong></summary>
            <div>
                <ul><li>- Obtain biopsies from at least two topographic sites: <b>antrum/incisura</b> and <b>corpus</b>.</li><li>- Place samples in <u>separately labeled jars</u>.</li><li>- Biopsy any additional suspicious areas separately.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Minor Differences in Biopsy Number</strong></summary>
            <div>
                <ul><li>- <b>AGA</b>: Recommends a minimum of <q>5 total biopsies</q> (antrum/incisura and corpus).</li><li>- <b>MAPS III</b>: Recommends <q>2 biopsies from antrum/incisura</q> and <q>2 from the corpus</q> (total of 4). An additional incisura biopsy is optional.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Role of H. pylori Eradication</strong></summary>
            <div>
                <ul><li>- <b>Strong Consensus</b>: <u>H. pylori eradication is essential</u> for both primary and secondary prevention of GC.</li></ul>
                
        <details>
            <summary><strong>Evidence for Eradication</strong></summary>
            <div>
                <ul><li>- <b>AGA</b>: Cites meta-analysis of non-US RCTs showing H. pylori eradication significantly reduces GC incidence by <q>46%</q> (NNT=72) and mortality by <q>39%</q> (NNT=135).</li><li>- <b>MAPS III</b>: Recommends eradication for all patients with precancerous conditions and after endoscopic or surgical therapy for GC.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Screening for H. pylori</strong></summary>
            <div>
                <ul><li>- <b>AGA</b>: Recommends <u>opportunistic screening</u> in high-risk individuals and considering 'familial-based testing' (screening adult household members).</li><li>- <b>MAPS III</b>: Suggests non-invasive screening for first-degree relatives of GC patients between ages <q>20-30</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Important Caveat</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: Eradication is an <u>adjunct</u>, not a replacement for endoscopic surveillance in patients who have already developed advanced precancerous changes (atrophy/GIM), as the risk of progression remains.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management of Endoscopic & Histologic Findings</strong></summary>
            <div>
                <ul><li>- Management is determined by the findings on the index screening/surveillance endoscopy.</li></ul>
                
        <details>
            <summary><strong>Normal Mucosa (No Atrophy, GIM, or Neoplasia)</strong></summary>
            <div>
                <ul><li>- <b>AGA</b>: The decision to continue screening is based on individual risk factors and patient preference. Consider ongoing screening every <q>3-5 years</q> for those with strong risk factors (e.g., family history).</li><li>- <b>MAPS III</b>: Follows population-based risk intervals (e.g., every 5 years in intermediate-risk regions).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Atrophic Gastritis (AG) & Gastric Intestinal Metaplasia (GIM)</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: Risk stratification is key. Patients with advanced changes require surveillance.</li></ul>
                
        <details>
            <summary><strong>High-Risk Features Warranting Surveillance</strong></summary>
            <div>
                <ul><li>- <b>AGA</b>: <u>Severe</u> atrophic gastritis, <u>multifocal</u> or <u>incomplete-type</u> GIM, extensive GIM, and family history of GC.</li><li>- <b>MAPS III</b>: Extensive endoscopic changes (Kimura C3+ or EGGIM 5+) or advanced histologic stages (<b>OLGA/OLGIM III/IV</b>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Surveillance Interval for High-Risk AG/GIM</strong></summary>
            <div>
                <ul><li>- <b>Strong Consensus</b>: High-quality endoscopy every <q><b>3 years</b></q>.</li><li>- <b>AGA</b> adds that shorter intervals may be advisable for those with multiple risk factors.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Low-Risk AG/GIM: No Surveillance</strong></summary>
            <div>
                <ul><li>- <b>MAPS III</b>: Explicitly recommends <u>no surveillance</u> for patients with mild to moderate atrophy or GIM restricted to the antrum, without other risk factors.</li><li>- <b>AGA</b>: Implies a similar approach by focusing surveillance on high-risk individuals.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Dysplasia</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: All dysplasia diagnoses should be confirmed by an <u>experienced GI pathologist</u> due to interobserver variability.</li></ul>
                
        <details>
            <summary><strong>Non-Visible Dysplasia (on biopsies)</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: Requires a repeat, high-quality EGD by an experienced endoscopist after H. pylori eradication.</li><li>- <b>Follow-up Interval</b>: Repeat EGD in <q>6 months</q> for High-Grade Dysplasia (HGD) and <q>6-12 months</q> for Low-Grade Dysplasia (LGD) or Indefinite for Dysplasia (IND).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Visible Dysplasia (Endoscopic Lesion)</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: Should undergo <b>endoscopic resection</b> (diagnostic and therapeutic) with the goal of en bloc, R0 resection.</li><li>- <b>AGA</b>: Notes that nearly <q>25%</q> of lesions with LGD on biopsy are up-staged after resection (<q>17%</q> to HGD, <q>7%</q> to carcinoma).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Early Gastric Cancer (EGC) & High-Grade Dysplasia (HGD)</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: <u>Endoscopic Submucosal Dissection (ESD)</u> is the treatment of choice for most lesions.</li></ul>
                
        <details>
            <summary><strong>MAPS III: Detailed ESD Indications</strong></summary>
            <div>
                <ul><li>- Provides highly specific criteria for selecting lesions for ESD.</li></ul>
                
        <details>
            <summary><strong>Standard Indications for ESD</strong></summary>
            <div>
                <ul><li>- <b>Differentiated lesions</b> (dysplasia or intramucosal carcinoma):</li><li>- Any size if <u>not ulcerated</u>.</li><li>- ≤<q>30 mm</q> if <u>ulcerated</u> (UL-I).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Expanded/Conditional Indications for ESD</strong></summary>
            <div>
                <ul><li>- <b>Differentiated lesions</b> with minimal submucosal invasion (SM1, ≤<q>500μm</q>) if size ≤<q>30 mm</q>.</li><li>- <b>Undifferentiated lesions</b> (intramucosal) if size ≤<q>20 mm</q> and <u>not ulcerated</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>MAPS III: Post-Resection Risk Stratification</strong></summary>
            <div>
                <ul><li>- Defines management based on the pathology of the resected specimen.</li></ul>
                
        <details>
            <summary><strong>Curative / Very Low-Risk Resection</strong></summary>
            <div>
                <ul><li>- <b>Criteria</b>: En bloc R0, pT1a, differentiated, no lymphovascular invasion (LVI), size ≤<q>30mm</q> if ulcerated.</li><li>- <b>LNM Risk</b>: < <q>0.5%–1%</q>.</li><li>- <b>Action</b>: <u>No further treatment</u> needed.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Curative / Low-Risk Resection</strong></summary>
            <div>
                <ul><li>- <b>Criteria</b>: En bloc R0, no LVI, AND either:</li><li>- pT1b (SM1 ≤<q>500μm</q>), differentiated, size ≤<q>30mm</q>.</li><li>- pT1a, undifferentiated, size ≤<q>20mm</q>, no ulceration.</li><li>- <b>LNM Risk</b>: < <q>3%</q>.</li><li>- <b>Action</b>: Complete staging; further treatment generally not needed after multidisciplinary discussion.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>High-Risk (Non-Curative) Resection</strong></summary>
            <div>
                <ul><li>- <b>Criteria</b>: Any of the following:</li><li>- Positive vertical margin (VM+).</li><li>- Lymphovascular invasion (LVI+).</li><li>- Deep submucosal invasion (> <q>500μm</q>).</li><li>- Undifferentiated with ulceration or size > <q>20mm</q>.</li><li>- Differentiated pT1b with size > <q>30mm</q>.</li><li>- <b>Action</b>: Complete staging and strong consideration for <u>additional treatment (surgery)</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Post-Resection Surveillance</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: All patients with resected gastric neoplasia require ongoing endoscopic surveillance indefinitely.</li><li>- <b>AGA</b>: Notes that specific intervals require more data for the US population but refers to other specialized guidelines.</li><li>- <b>MAPS III</b>: Implies surveillance is needed but does not specify intervals in the main recommendations.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management of Type I Gastric Carcinoids (gNETs)</strong></summary>
            <div>
                <ul><li>- <b>AGA Specific Guidance</b>: This topic is covered in detail by the AGA CPU but not the MAPS III guideline.</li></ul>
                
        <details>
            <summary><strong>Pathophysiology & Risk</strong></summary>
            <div>
                <ul><li>- Type I gNETs account for <q>70-80%</q> of all gNETs.</li><li>- Arise in the setting of <b>corpus atrophy</b> (from H. pylori or autoimmune gastritis) leading to hypergastrinemia.</li><li>- Typically indolent with low metastatic potential, especially when small.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management by Size</strong></summary>
            <div>
                <ul><li>- <b>< 1 cm</b>: May consider resection.</li><li>- <b>1–2 cm</b>: <u>Should be endoscopically resected</u>.</li><li>- <b>> 2 cm</b>: High risk of metastasis. Requires cross-sectional imaging and referral for <u>surgical resection</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Surveillance</strong></summary>
            <div>
                <ul><li>- Patients with Type I gNETs require surveillance, but intervals are not well defined.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>De-escalation of Screening & Surveillance</strong></summary>
            <div>
                <ul><li>- <b>Strong Consensus</b>: Screening and surveillance should only be performed on individuals who are fit for subsequent endoscopic or surgical treatment.</li></ul>
                
        <details>
            <summary><strong>Criteria for Stopping</strong></summary>
            <div>
                <ul><li>- <b>AGA</b>: Stop when a person is no longer fit for treatment. Decision should balance life expectancy, risks, and patient preferences.</li><li>- <b>MAPS III</b>: Suggests discontinuing or not starting in asymptomatic individuals over age <q><b>80</b></q> and considering comorbidities.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Implementation & Health Equity</strong></summary>
            <div>
                <ul><li>- <b>AGA Emphasis</b>: The US guideline places a strong emphasis on achieving health equity, addressing modifiable risk factors (poverty, diet, smoking), and overcoming barriers to care that disproportionately affect high-risk groups.</li><li>- <b>MAPS III Emphasis</b>: Focuses on cost-effectiveness, feasibility, and minimizing environmental impact ('green endoscopy').</li></ul>
                
        <details>
            <summary><strong>Future Directions & Research Gaps</strong></summary>
            <div>
                <ul><li>- <b>Consensus</b>: Need for better, non-invasive biomarkers for risk stratification to reduce the burden of endoscopy.</li><li>- <b>AGA</b>: Highlights that GC is among the lowest-funded cancers by the NIH/NCI in the US.</li><li>- <b>MAPS III / AGA</b>: Both see promise in Artificial Intelligence (AI) for improving detection, but agree data is too preliminary for routine recommendation.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
